INSIGHTS ON PHARMACEUTICAL LOGISTICS

• Strengthen Pharmaceutical Supply Chains With A U.S.-Based CDMO

  While certain ingredients require sourcing abroad, partnering with a U.S.-based company that owns its manufacturing assets allows for direct oversight of product quality and supply reliability.

• Collaborative Supply Chain Management In A Fragmented World

  Biopharma supply chains are under pressure. As regionalization accelerates, success depends on agility, trust, and new approaches to collaboration that can withstand ongoing global uncertainty.

• Site Transfer Of Tablet Production From Ex-U.S. To Georgia Site

  Explore how strategic U.S.-based manufacturing and supply chain diversification can reduce risk, lower costs, and enhance supply reliability for pharmaceutical products.

• Building A Purification Toolkit For An Expanding Variety Of mAb Therapeutics

  Explore techniques for optimizing purification toolkits for various monoclonal antibody formats. This session covers resin and buffer selection for efficient downstream process development.

• Shedding Light On Photo-Stability Forced Degradation

  11/26/2024

  Ensure the stability and safety of your drug products by utilizing comprehensive forced degradation and photo-stability testing, guided by ICH and FDA standards, to identify degradation pathways and assess light exposure risks.

• GLP-1 INJ Solid Phase Peptide Synthesis (SPPS) Workflow

  6/29/2026

  Scale your GLP-1 peptide synthesis efficiently. Discover how automated solid-phase workflows and single-use fluidics maximize crude purity while reducing total solvent consumption.

• From LAL To rFC: The Evolution Of Endotoxin Testing

  6/26/2026

  Protect patient safety and ensure regulatory compliance by implementing sensitive, reliable bacterial endotoxin testing as a critical component of pharmaceutical quality assurance.

• Building A Resilient Supply Chain For Your Next-Generation Peptide Therapeutic

  1/23/2025

  As peptide therapeutics continue to establish themselves as a leading technology for treating chronic indications, drug sponsors must identify reliable peptide building block suppliers to secure high-quality starting materials.

• Fast-Track Innovation, Address CMC Challenges In Expedited Pathways

  1/26/2026

  Learn to overcome solubility challenges and utilize flexible development strategies to transition innovative treatments from early-phase trials to commercialization while ensuring patient safety.